Abstract Number: 1111 • 2019 ACR/ARP Annual Meeting
Lupus Teledematology: A Pilot Project to Evaluate the Plausibility of a Rapid Access Dermatology Service for Lupus Patients
Background/Purpose: Clinicians have been increasingly using social media sites professionally. Platforms such as WhatsApp ® could be a potentially effective tool in teledermatology for rapid diagnosis and/or…Abstract Number: 1626 • 2019 ACR/ARP Annual Meeting
Baseline Serum Osteopontin (OPN) Level Is Associated with Early Coronary Artery-calcification and Its Progression in Patients with Systemic Lupus Erythematosus
Background/Purpose: Background/purpose Premature atherosclerosis has been recognized as a major cause of morbidity and mortality in SLE patients. We aimed to determine 1) the incidence…Abstract Number: 2571 • 2019 ACR/ARP Annual Meeting
Early Improvement in SLEDAI-2K Responder Index-50 Predicts SRI-4 Response in a Randomized Placebo-Controlled Trial of Ustekinumab (UST) in Systemic Lupus Erythematosus
Background/Purpose: While traditional Systemic Lupus Erythematosus (SLE) Disease Activity Index 2000 (SLEDAI-2K) scoring assesses complete SLE response for individual disease manifestations, the SLEDAI-2K Responder Index-50…Abstract Number: 666 • 2019 ACR/ARP Annual Meeting
Sensitivity to Change of the Patient Reported Outcomes Measurement Information System (PROMIS) Computerized Adaptive Test (CAT) Measures in a Single Canadian Lupus Cohort
Background/Purpose: Patient-reported outcomes (PROs) measures are a key component of the care of patients with systemic lupus erythematosus (SLE). The Patient Reported Outcomes Measurement Information…Abstract Number: 1124 • 2019 ACR/ARP Annual Meeting
The Direct and Indirect Costs of Illness Associated with Systemic Lupus Erythematosus in the USA, UK, France, and Germany: A Structured Review
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease. SLE tends to peak during prime working years, resulting in a high economic burden due…Abstract Number: 1729 • 2019 ACR/ARP Annual Meeting
Infections and Mortality in 230 Childhood Lupus Patients: A Single Center Experience from North India
Background/Purpose: Children with systemic lupus erythematosus(cSLE) have more severe disease as compared to adults. Additionally, Asians in their geographic area have high burden of infections…Abstract Number: 2576 • 2019 ACR/ARP Annual Meeting
Clinical Evidence Supporting Therapeutic Potential of Activating the Immune Checkpoint Receptor BTLA in SLE
Background/Purpose: Background/Purpose: Immune checkpoint inhibitors have demonstrated durable benefit in some cancer patients. However, checkpoint inhibitors are also associated with new onset autoimmune adverse events. …Abstract Number: 676 • 2019 ACR/ARP Annual Meeting
Cluster Profiling of Patients in a Real-World Data Set with Systemic Lupus Erythematosus and Their Associated Treatments
Background/Purpose: Previous systemic lupus erythematosus (SLE) studies have identified potential clusters of SLE clinical manifestations. To describe the presentation of SLE across different cohorts of patients…Abstract Number: 1185 • 2019 ACR/ARP Annual Meeting
New Imaging Modality to Evaluate Arthritis in Lupus Based on Frequency-domain Optical Transmission
Background/Purpose: 95% of the people with SLE experience joint pain, stiffness and swelling at some time during their illness. It is currently difficult to both…Abstract Number: 1730 • 2019 ACR/ARP Annual Meeting
Impact of Preceding and Co-existing Autoimmune Cytopenias on Severity of Childhood-onset Systemic Lupus Erythematosus: A Single-Center Retrospective Cohort Study
Background/Purpose: Autoimmune cytopenias may precede or occur with childhood-onset systemic lupus erythematosus (cSLE). Adult studies suggest that lupus patients with concurrent autoimmune cytopenias have relatively…Abstract Number: 2580 • 2019 ACR/ARP Annual Meeting
Pharmacotherapies Targeting Type 2 SLE Symptoms
Background/Purpose: We propose categorizing lupus activity to better align with patient experience: Type 1 SLE activity includes classic symptoms such as arthritis and nephritis; Type…Abstract Number: 689 • 2019 ACR/ARP Annual Meeting
Patterns of High Disease Activity Status and Outcomes in Systemic Lupus Erythematosus
Background/Purpose: High Disease Activity Status (HDAS), defined as ever attainment of SLEDAI-2k of 10 or greater, may be a useful indicator of overall disease severity in…Abstract Number: 1199 • 2019 ACR/ARP Annual Meeting
Improving Rates of Cervical Cancer Screening and HPV Vaccination in Patients with Lupus
Background/Purpose: Patients with lupus have higher rates of cervical dysplasia and pre-malignant cervical lesions. At our institution, an urban referral center for patients with lupus, rates…Abstract Number: 1734 • 2019 ACR/ARP Annual Meeting
Low Bone Mineral Density Was Associated with Lupus Nephritis Irrespective of Duration on Steroid Treatment in a Large Observational Study of Juvenile Systemic Lupus Erythematosus Patients
Background/Purpose: An estimated 10-20% of all patients with systemic lupus erythematosus (SLE) develop clinical disease before the age of 18 years and are therefore classified…Abstract Number: 2584 • 2019 ACR/ARP Annual Meeting
Management of Cutaneous Manifestations of Lupus Erythematosus: A Systematic Review
Background/Purpose: Cutaneous lupus erythematosus (CLE), occurring with or without systemic lupus erythematosus (SLE), is a group of inflammatory skin diseases that can be very debilitating,…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 31
- Next Page »